- Trial phase
- Filed/BLA under FDA review (PDUFA December 23, 2026)
- Time to market
- If approved, commercial launch could begin in early 2027 following the December 23, 2026 PDUFA date. Gilead has stated launch preparations are underway.
- Why 7/10
- The next hard, dated catalyst is the PDUFA decision on December 23, 2026 (approximately 54 days away). Anito-cel is a major value driver for Gilead (the company paid $7.8B to acquire full ownership), but Gilead is a large-cap diversified biopharma with substantial HIV and other oncology revenue, so the drug is not make-or-break for the entire company. Score 7 reflects a near-term binary regulatory event on a significant but not sole asset.
The single most important catalyst is the FDA PDUFA decision on December 23, 2026. An approval would likely drive GILD shares higher as it validates the $7.8B Arcellx acquisition and adds a potentially best-in-class CAR-T to Gilead's oncology portfolio. A Complete Response Letter (rejection) would be a significant negative, though the strong efficacy and clean safety data from iMMagine-1 and the Phase 1 NEJM publication reduce that probability. Watch for any FDA Advisory Committee meeting announcement between now and December, which would add an additional binary event.
Price Chart
Executive Summary
Anito-cel (anitocabtagene autoleucel) is a BCMA-directed CAR-T cell therapy for multiple myeloma, developed by Gilead Sciences (GILD) through its Kite subsidiary after acquiring Arcellx for $7.8B in April 2026. The FDA accepted the BLA in February 2026 with a PDUFA target action date of December 23, 2026, based on the pivotal Phase 2 iMMagine-1 study that showed a 96% overall response rate and a differentiated safety profile versus approved competitor Carvykti. A Phase 3 trial (iMMagine-3) is ongoing in earlier treatment lines, and a Phase 1 autoimmune indication (generalized myasthenia gravis) is also being explored. The December PDUFA is the key near-term binary catalyst.
How It Works
Anito-cel is a one-time cell therapy (CAR-T) that reprograms a patient's own immune T cells to recognize and kill cancer cells bearing the BCMA protein, which is found on the surface of multiple myeloma cells. It uses a novel synthetic D-domain binder (ddBCMA) that the developer says binds BCMA more gently, potentially causing less inflammation and fewer side effects than existing CAR-T therapies.
Trial Status
The FDA accepted the Biologics License Application (BLA) for anito-cel as a fourth-line treatment for relapsed/refractory multiple myeloma in February 2026, supported by the pivotal Phase 2 iMMagine-1 study (NCT05396885) and a Phase 1 study (NCT04155749). The iMMagine-1 trial enrolled 117 heavily pretreated patients and reported a 96% overall response rate, 74% stringent complete response/complete response rate, and 95% minimal residual disease negativity at a median 15.9 months of follow-up. The Phase 1 study, published in the New England Journal of Medicine in September 2026, showed a 100% response rate with 79% complete responses across 38 treated patients. A Phase 3 trial (iMMagine-3, NCT06413498) is enrolling approximately 450 patients in earlier lines (1-3 prior therapies) with estimated primary completion in July 2028. A Phase 1 study in generalized myasthenia gravis (NCT06626919) is also recruiting.
The Two-Sided Case
Upcoming Catalysts
- PDUFA decision date December 23, 2026 for anito-cel in 4L+ relapsed/refractory multiple myeloma
- Potential FDA Advisory Committee meeting (if scheduled) before the PDUFA date
- iMMagine-3 Phase 3 enrollment updates in earlier-line multiple myeloma
Source Filing
The SecBot filing or press-release report that triggered this drug report:
GILEAD SCIENCES, INC. 8-K GILD ·Originating report